Clinical Trial Update: A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias [Phase 1]

View source ↗

Summary

Clinical trial update for CBX-250 in relapsed or refractory myeloid leukemias (Phase 1) that is currently recruiting at Crossbow Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• CBX-250

Snippet

Sponsor: Crossbow Therapeutics, Inc. | Conditions: High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Status: RECRUITING